ArticleDiscover oncology2026
Integrated multi-omics reveals the ITGB2-IL2RB-NK axis in promoting papillary thyroid carcinoma progression and immune microenvironment crosstalk.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPapillary thyroid carcinoma (PTC) is the most common thyroid malignancy, with some cases exhibiting aggressive features and therapeutic resistance. Dysregulated protein interaction networks and remodeling of the immune microenvironment have been increasingly recognized as critical in PTC progression. However, the genetic, protein, and immune regulatory networks involved in PTC have yet to be systematically elucidated. To address this gap, we employed an integrated multi-omics and genetic epidemiological approach. METHODOLOGY: This study employed a multi-stage integrated analysis strategy combining Mendelian randomization (MR), mediation analysis, and bioinformatics validation. First, MR was applied using protein quantitative trait loci (pQTL) data from the deCODE and UK Biobank Pharma Proteomics Project (UKB-PPP) databases, together with PTC genome-wide association study (GWAS) data from FinnGen, to screen for PTC-associated proteins. Second, a two-step mediation analysis was conducted to construct protein–protein interaction (PPI) networks and immune microenvironment regulatory networks. Finally, differential expression and co-expression analyses were performed using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases to validate the functional relevance of the identified networks.
resultsWe identified the ITGB2 (integrin β2)-IL2RB (interleukin-2 receptor β)-natural killer (NK) cell regulatory axis, which was significantly associated with PTC risk. This regulatory axis exhibited marked differential expression and co-expression relationships in PTC tissues, confirming its functional relevance.
conclusionThis study establishes a causal regulatory chain of "ITGB2-IL2RB-NK cell" in PTC through integrated multi-omics and genetic epidemiological approaches. This work provides a theoretical basis for developing combined immunotherapy strategies targeting components of the ITGB2-IL2RB-NK cell regulatory axis within the tumor microenvironment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.